- Diagnostic Différentiel
Drug Information for CefTRIaxONE for injection and Dextrose Injection (B. Braun Medical Inc.): CONTRAINDICATIONS
- CLINICAL PHARMACOLOGY
- INDICATIONS AND USAGE
- ADVERSE REACTIONS
- DOSAGE AND ADMINISTRATION
- ANIMAL PHARMACOLOGY
- HOW SUPPLIED
- Liens externes liés à CefTRIaxONE for injection and Dextrose Injection (B. Braun Medical Inc.)
Ceftriaxone for Injection and Dextrose Injection is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.
Neonates (≤28 days)
Hyperbilirubinemic neonates, especially prematures, should not be treated with Ceftriaxone for Injection and Dextrose Injection. In vitro studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin and bilirubin encephalopathy can possibly develop in these patients.
Ceftriaxone for Injection and Dextrose Injection must not be co-administered with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition, in neonates because of the risk of precipitation of ceftriaxone-calcium salt. Cases of fatal reactions with ceftriaxone-calcium precipitates in lung and kidneys in neonates have been described. In some cases the infusion lines and the times of administration of ceftriaxone and calcium-containing solutions differed.
For information regarding all other patients, see WARNINGS.
Solutions containing dextrose may be contraindicated in patients with hypersensitivity to corn products.
- Drug Information Provided by National Library of Medicine (NLM).